Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.26)
# 2,568
Out of 4,839 analysts
207
Total ratings
38.14%
Success rate
-1.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $21.55 | +11.37% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $3.92 | +410.20% | 3 | May 19, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $52 | $25.78 | +101.71% | 3 | May 19, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $35.52 | +83.00% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $107.88 | +53.87% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $8.08 | +110.40% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $4.26 | +698.12% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $62.14 | +15.87% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $45.47 | +53.95% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $119.12 | +25.92% | 26 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.20 | +234.73% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $48.06 | +76.86% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.90 | +343.04% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $12.69 | +112.77% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.02 | +24.53% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $30.49 | +119.78% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $6.27 | +91.54% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.47 | +313.22% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $30.11 | +132.48% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.90 | +342.18% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $7.88 | -49.24% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.76 | +425.97% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $4.99 | +2,705.61% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.45 | +865.52% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $2.21 | +126.76% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $0.80 | +273.60% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.32 | +960.61% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.44 | +309.84% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $42.86 | -48.67% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $15.43 | +862.41% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.65 | +3,536.36% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $2.98 | +101.34% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.49 | +10,880.07% | 6 | May 8, 2020 |
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.55
Upside: +11.37%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $3.92
Upside: +410.20%
CG Oncology
May 19, 2025
Maintains: Overweight
Price Target: $55 → $52
Current: $25.78
Upside: +101.71%
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $35.52
Upside: +83.00%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $107.88
Upside: +53.87%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $8.08
Upside: +110.40%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $4.26
Upside: +698.12%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $62.14
Upside: +15.87%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $45.47
Upside: +53.95%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $119.12
Upside: +25.92%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.20
Upside: +234.73%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $48.06
Upside: +76.86%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.90
Upside: +343.04%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $12.69
Upside: +112.77%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.02
Upside: +24.53%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $30.49
Upside: +119.78%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $6.27
Upside: +91.54%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $8.47
Upside: +313.22%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $30.11
Upside: +132.48%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.90
Upside: +342.18%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $7.88
Upside: -49.24%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.76
Upside: +425.97%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $4.99
Upside: +2,705.61%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.45
Upside: +865.52%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $2.21
Upside: +126.76%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $0.80
Upside: +273.60%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.32
Upside: +960.61%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.44
Upside: +309.84%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $42.86
Upside: -48.67%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $15.43
Upside: +862.41%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.65
Upside: +3,536.36%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $2.98
Upside: +101.34%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.49
Upside: +10,880.07%